Étiquette : système endocannabinoïde

Role of the endogenous cannabinoid system in nicotine addiction : novel insights, Islam Hany Gamaleddin et al., 2015

Role of the endogenous cannabinoid system in nicotine addiction : novel insights Islam Hany Gamaleddin, Jose M.Trigo, Aliou B. Gueye, Alexander Zvonok, Alexandros Makriyannis, Steven R. Goldberg and Bernard Le Foll Frontiers in Psychiatry, 2015, Vol 6, Article 41, 1-12. doi : 10.3389/fpsyt.2015.00041 Several lines of evidence have shown that the endogenous cannabinoids are implicated in several neuropsychiatric diseases. Notably, preclinical and human clinical studies have shown a pivotal role of the cannabinoid system in nicotine addiction. The CB1 receptor inverse agonist/antagonist rimonabant (also known as SR141716)was effective to decrease nicotine-taking and nicotine-seeking in rodents, as well as the elevation of dopamine induced by [...]

Lire la suite

Cannabinomimetric Lipids : From Natural Extract to Artificial Synthesis, Ya-Ru Gao & Yong-Qiang Wang, 2018

Cannabinomimetric Lipids : From Natural Extract to Artificial Synthesis Ya-Ru Gao, Yong-Qiang Wang Natural Products and Bioprospecting, 2018, 8, 1–21 doi : 10.1007/s13659-017-0151-9 Abstract Endocannabinoid system is related with various physiological and cognitive processes including fertility, pregnancy, during pre- and postnatal development, pain-sensation, mood, appetite, and memory. In the latest decades, an important milestone concerning the endocannabinoid system was the discovery of the existence of the cannabinoid receptors CB1 and CB2. Anandamide was the first reported endogenous metabolite, which adjusted the release of some neurotransmitters through binding to the CB1 or CB2 receptors. Then a series of cannabinomimetric lipids were extracted from marine organisms, which [...]

Lire la suite

IACM : Le premier webinaire gratuit de l’IACM commence dans 3 heures : Dr Roger Pertwee

Dans 3 heures, le premier webinaire de la série d'événements gratuits de l'IACM commencera, qui se déroulera jusqu'au 3 décembre 2020. Tous les webinaires peuvent être consultés gratuitement jusqu'au 31 mars 2021. Il n'y a donc aucun problème si vous manquez un rendez-vous. O. k. Vous pouvez copier le Magath ici https://new.cannabis-med.org/e2020 15 octobre 2020, 18 heures (CET) Dr. Roger Pertwee Les utilisations thérapeutiques potentielles de certains cannabinoïdes dérivés du cannabis et synthétiques révélées par leurs propriétés pharmacologiques -- Quels sont les médicaments cannabinoïdes approuvés qui ont déjà été développés ? -- Existe-t-il des cannabinoïdes végétaux (phytocannabinoïdes) ayant des propriétés pharmacologiques, pour lesquels des applications thérapeutiques [...]

Lire la suite

The role of cannabinoid transmission in emotional memory formation : implications for addiction and schizophrenia, Huibing Tan et al., 2014

The role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia Huibing Tan, Tasha Ahmad, Michael Loureiro, Jordan Zunder and Steven R. Laviolette Frontiers in Psychiatry, 2014,Vol 5, Article 73, 1-12 doi : 10.3389/fpsyt.2014.00073   Emerging evidence from both basic and clinical research demonstrates an important role for endo-cannabinoid (ECB) signaling in the processing of emotionally salient information, learning, and memory. Cannabinoid transmission within neural circuits involved in emotional processing has been shown to modulate the acquisition, recall, and extinction of emotionally salient memories and importantly, can strongly modulate the emotional salience of incoming sensory information. Two neural regions in particular, the [...]

Lire la suite

Activation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury, Jérémie Joffre et al., 2020,

Activation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury Jérémie Joffre, Che-Chung Yeh, Erika Wong, Mayuri Thete, Fengyun Xu, Ivana Zlatanova, Elliot Lloyd, Lester Kobzik, Matthieu Legrand, and Judith Hellman The Journal of Immunology, 2020, 204: 1–20. doi : 10.4049/jimmunol.2000213   Cannabis sativa and its principal components, D9-tetrahydrocannabinol (D9-THC) and cannabidiol, are increasingly being used to treat a variety of medical problems, including inflammatory conditions. Although studies suggest that the endocannabinoid system has immunomodulatory properties, there remains a paucity of information on the effects of cannabinoids on immunity and on outcomes of infection and injury. [...]

Lire la suite

Cannabinoids in Gynecological Diseases, Petra Luschnig et al., 2019

Cannabinoids in Gynecological Diseases Petra Luschnig, Rudolf Schicho Medical Cannabis & Cannabinoids, 2019, 2, 14-21 Doi : 10.1159/000499164   Abstract The endocannabinoid system (ECS) is a multifunctional homeostatic system involved in many physiological and pathological conditions. The ligands of the ECS are the endocannabinoids, whose actions are mimicked by exogenous cannabinoids, such as phytocannabinoids and synthetic cannabinoids. Responses to the ligands of the ECS are mediated by numerous receptors like the classical cannabinoid receptors (CB1 and CB2) as well as ECS-related receptors, e.g., G protein-coupled receptors 18 and 55 (GPR18 and GPR55), transient receptor potential ion channels, and nuclear peroxisome proliferator-activated receptors. The ECS regulatesalmost all levels of [...]

Lire la suite

Cannabinol inhibits proliferation and induces cell cycle arrest and apoptosis in glioblastoma, hepatocellular carcinoma and breast cancer cells, Nuanying Zhong, 2020

Cannabinol inhibits proliferation and induces cell cycle arrest and apoptosis in glioblastoma, hepatocellular carcinoma and breast cancer cells Nuanying ZHONG, Thesis, Master of Science in Biological Sciences Faculty of Arts and Science, Department of Biological Sciences, University of Lethbridge Research Repository, Canada 2020 https://hdl.handle.net/10133/5697   ABSTRACT Cannabis sativa is an agriculturally and medicinally plant with many pharmaceutical properties. Cancer is a deadly disease; it is estimated that it will cause over 80 thousand deaths in 2019 in Canada. Although numerous studies have demonstrated that cannabinoids have anti-tumorous properties in various cancers, the anti-malignant activities of cannabinol (CBN) on carcinogenesis and underlying mechanisms remain largely unknown. In this study, we [...]

Lire la suite

High Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity, Marie Fitzgibbon et al., 2016

High Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity Marie Fitzgibbon, David P. Finn,  Michelle Roche International Journal of Neuropsychopharmacology, 2016, 19, (3), 1–20 doi : 10.1093/ijnp/pyv095   Abstract Depression and pain are two of the most debilitating disorders worldwide and have an estimate co-occurrence of up to 80%. Comorbidity of these disorders is more difficult to treat, associated with significant disability and impaired healthrelated quality of life than either condition alone, resulting in enormous social and economic cost. Several neural substrates have been identified as potential mediators in the association between depression and pain, including neuroanatomical reorganization, monoamine and neurotrophin depletion, dysregulation [...]

Lire la suite

BIBLIOGRAPHIE : Système endocannabinoïdes et récepteurs aux cannabinoïdes, Dr Christian Sueur, GRECC, avril 2020.

BIBLIOGRAPHIE : Système endocannabinoïdes et récepteurs aux cannabinoïdes   Dr Christian Sueur, GRECC, avril 2020.     1 - Système endocannabinoïde : 1 - 7 2 - Récepteurs des cannabinoïdes : 8 - 13 3 - THC et récepteurs non-cannabinoïdes : 14 4 - CBD et récepteurs non cannabinoïdes : 15 5 - Neurophysiologie des endocannabinoïdes : 16 - 19 6 - Neuropharmacologie des cannabinoïdes de synthèse : 20 - 21 7 - Neuropharmacologie des Phytocannabinoïdes : 22 - 29    

Lire la suite